Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 7/20 | 0.67 |
| ▸ | NR3C1 | P04150 | 13/20 | 0.63 |
| ▸ | PGR | P06401 | 11/20 | 0.63 |
| ▸ | ESR1 | P03372 | 3/20 | 0.56 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10399827 | 1.00 | AR (0.67) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL3678661 | 1.00 | AR (0.67) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL15094157 | 1.00 | AR (0.67) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL9146687 | 0.94 | AR (0.58) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL14656547 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL9740103 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL14666086 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL20235298 | 0.92 | AR (0.57) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL5395107 | 0.92 | AR (0.71) | ARNR3C1PGRESR1NR3C2 | |
| SCHEMBL5395109 | 0.92 | AR (0.71) | ARNR3C1PGRESR1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1239829-B1 | DEVICES FOR THE DELIVERY OF DRUGS HAVING ANTIPROGESTINIC PROPERTIES | BAYER SCHERING PHARMA OY (FI) | 2008-07-23 | — | — | EP | claimed |
| EP-0787002-B1 | COMPETITIVE PROGESTERONE ANTAGONISTS FOR REGULATING FEMALE FERTILITY AS REQUIRED | SCHERING AG (DE) | 2006-12-13 | — | — | EP | claimed |
| EP-0889727-B1 | SEQUENTIAL OESTROGEN/PROGESTERONE ANTAGONIST COMBINATION FOR HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2006-03-08 | — | — | EP | claimed |
| US-20050064031-A1 | Combination contraceptive, kits that contain the latter, and a method that uses the latter | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | claimed |
| US-6362237-B1 | MIXTURE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-03-26 | — | — | US | claimed |
| US-6143754-A | Competitive progesterone antagonist for demand-oriented female birth control | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | claimed |
| US-5089635-A | Antiprogesterone, antiglucocorticoids | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | claimed |
| EP-2779996-B1 | DRUG DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF BIOACTIVE AGENTS | UPM KYMMENE CORP (FI) | 2024-04-10 | — | — | EP | disclosed |
| US-11389537-B2 | Drug delivery system for sustained delivery of bioactive agents | UPM-KYMMENE CORPORATION (FI) | 2022-07-19 | — | — | US | disclosed |
| US-20140322327-A1 | DRUG DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF BIOACTIVE AGENTS | UPM-KYMMENE CORPORATION (FI) | 2014-10-30 | — | — | US | disclosed |
| EP-1239829-B1 | DEVICES FOR THE DELIVERY OF DRUGS HAVING ANTIPROGESTINIC PROPERTIES | BAYER SCHERING PHARMA OY (FI) | 2008-07-23 | — | — | EP | disclosed |
| EP-0787002-B1 | COMPETITIVE PROGESTERONE ANTAGONISTS FOR REGULATING FEMALE FERTILITY AS REQUIRED | SCHERING AG (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-20020169205-A1 | Implantation rates after in vitro fertilization, and treatment of infertility and early pregnancy loss with a nitric oxide donor or substrate alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors in combination with antiprogestins or other agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2002-11-14 | — | — | US | disclosed |
| US-6143754-A | Competitive progesterone antagonist for demand-oriented female birth control | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-11-07 | — | — | US | disclosed |
| EP-0723439-B1 | COMBINATION OF PROGESTERONE ANTAGONISTS AND ANTI-OESTROGENS WITH PARTIAL AGONISTIC ACTION FOR USE IN HORMONE-REPLACEMENT THERAPY FOR PERI- AND POST-MENOPAUSAL WOMEN | SCHERING AG (DE) | 2000-09-13 | — | — | EP | disclosed |
| US-6040340-A | NITRIC OXIDE SYNTHASE SUBSTRATE | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-03-21 | — | — | US | disclosed |
| US-5719136-A | Combination of progesterone antagonists and antiestrogens with partial agonistic action for hormone substitution therapy for perimenopausal and postmenopausal women | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-02-17 | — | — | US | disclosed |
| US-5089635-A | Antiprogesterone, antiglucocorticoids | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-02-18 | — | — | US | disclosed |
| EP-0190759-B1 | 11-BETA PHENYL GONANES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-08-30 | — | — | EP | disclosed |
| EP-0190759-A2 | 11-Beta phenyl gonanes, their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064031-A1 | Combination contraceptive, kits that contain the latter, and a method that uses the latter | GNRHR, PGRMC2, SHBG | AR 244/4885NR3C1 120/4885PGR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.